KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Operating Expenses: 2009-2024

Historic Operating Expenses for Nektar Therapeutics (NKTR) over the last 16 years, with Dec 2024 value amounting to $203.6 million.

  • Nektar Therapeutics' Operating Expenses fell 25.67% to $43.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $160.7 million, marking a year-over-year decrease of 34.73%. This contributed to the annual value of $203.6 million for FY2024, which is 42.45% down from last year.
  • Nektar Therapeutics' Operating Expenses amounted to $203.6 million in FY2024, which was down 42.45% from $353.8 million recorded in FY2023.
  • Over the past 5 years, Nektar Therapeutics' Operating Expenses peaked at $578.0 million during FY2020, and registered a low of $203.6 million during FY2024.
  • Over the past 3 years, Nektar Therapeutics' median Operating Expenses value was $353.8 million (recorded in 2023), while the average stood at $341.9 million.
  • As far as peak fluctuations go, Nektar Therapeutics' Operating Expenses grew by 4.21% in 2020, and later tumbled by 42.45% in 2024.
  • Over the past 5 years, Nektar Therapeutics' Operating Expenses (Yearly) stood at $578.0 million in 2020, then dropped by 5.19% to $548.0 million in 2021, then fell by 14.56% to $468.2 million in 2022, then dropped by 24.44% to $353.8 million in 2023, then plummeted by 42.45% to $203.6 million in 2024.